Fulgent Genetics, Inc.

8-K · flgt-20260601.htm iXBRL

0001674930 2026-06-01 2026-06-01

  

 !
  
 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
  
 Date of Report (Date of earliest event reported): June 1, 2026
  
 FULGENT GENETICS, INC.
 (Exact Name of Registrant as Specified in Charter)
  

 Delaware

 001-37894

 81-2621304

 (State or other jurisdiction of
 incorporation)

 (Commission File Number)

 (IRS Employer Identification No.)

  

 4399 Santa Anita Avenue
 El Monte , California

 91731

 (Address of Principal Executive Offices)

 (Zip Code)

  
 ( 626 ) 350-0537
 (Registrant’s telephone number, including area code)
  
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
  

 ☐

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 ☐

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 ☐

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 ☐

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  
 Securities registered pursuant to Section 12(b) of the Act:
  

 Title of each class

  

 Trading Symbol(s)

  

 Name of each exchange on which registered

 Common Stock, par value $0.0001 per share

  

 FLGT

  

 The Nasdaq Stock Market  
(Nasdaq Global Market)

  
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company ☐
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
  
  
  

  

  

 Item 8.01	Other Events.
 On June 1, 2026, Fulgent Genetics, Inc. (the “Company”) issued a press release announcing that the Company will present updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session based on the Company's full abstract entitled “ FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020 ”, previously released on May 21, 2026. A copy of the Company’s press release containing this information is filed as Exhibit 99.1 to this Current Report on Form 8-K.

 Item 9.01	Financial Statements and Exhibits.
 (d)	Exhibits.
  

 Exhibit
 No.

  

 Description

 99.1

  

 Press Release dated June 1, 2026

 104

  

 Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

  

  

 SIGNATURE
 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
  

 Date: June 1, 2026

 FULGENT GENETICS, INC.

  

  

  

  

  

 By:

  

 /s/ Paul Kim

  

 Name:

  

 Paul Kim

  

 Title:

  

 Chief Financial Officer